Related Experiment Video
Updated: Sep 13, 2025

Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet
Published on: January 3, 2017
Ashwa.30: A Bioactive-Optimized Ashwagandha Extract for Clinically Validated Low-Dose Efficacy
Abstract:
Ashwa.30 is a clinically validated, dual-standardized extract of Withania somnifera developed using Bioactive Optimization Technology (B.O.T.). Unlike conventional high-dose ashwagandha products, Ashwa.30 achieves efficacy at a low 30 mg/day dosage through a synergistic combination of withanolides and a proprietary ATP-active fraction. Preclinical and clinical studies demonstrate significant improvements in endurance, stress resilience, and overall well-being. This manuscript summarizes the unique scientific rationale, development process, mechanisms of action, and formulation advantages of Ashwa.30, making it a next-generation solution for integrative and functional health applications.
More Related Videos
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
10:33Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells
Published on: November 18, 2022
Related Concept Videos
Dose-Response Relationship: Potency and Efficacy
Bioequivalence: Overview
Therapeutic Index
Bioavailability: Overview
Dose-Response Relationship: Overview
Drug Discovery: Overview